Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.
It paid its median employee $312,109 last year. Dicerna Pharmaceuticals Dicerna Pharmaceuticals is on a mission to hire people, and that means offering an attractive pay package. The median ...
Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist. The big pharma company is also paying $100 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback